{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T04:22:10Z","timestamp":1768191730726,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T00:00:00Z","timestamp":1420416000000},"content-version":"vor","delay-in-days":948,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.jbo.2012.02.001","type":"journal-article","created":{"date-parts":[[2012,4,19]],"date-time":"2012-04-19T15:16:35Z","timestamp":1334848595000},"page":"24-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases"],"prefix":"10.1016","volume":"1","author":[{"given":"Carlo C.","family":"Quattrocchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Dell'Aia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Errante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomena","family":"Occhicone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Virz\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Beomonte Zobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jbo.2012.02.001_bib1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nature Reviews Cancer"},{"issue":"14","key":"10.1016\/j.jbo.2012.02.001_bib2","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2004.08.181","article-title":"Bone imaging in metastatic breast cancer","volume":"22","author":"Hamaoka","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.02.001_bib3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/bjc.1977.42","article-title":"Assessment of response to therapy in advanced breast cancer","volume":"35","author":"Hayward","year":"1977","journal-title":"British Journal of Cancer"},{"issue":"Suppl. 8","key":"10.1016\/j.jbo.2012.02.001_bib4","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I","article-title":"Mechanisms of bone metastasis","volume":"80","author":"Mundy","year":"1997","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jbo.2012.02.001_bib5","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.orthres.2003.03.004","article-title":"Bone resorption activity of osteolytic metastatic lung and breast cancers","volume":"22","author":"Shih","year":"2004","journal-title":"Journal of Orthopaedic Research"},{"issue":"Suppl. 1","key":"10.1016\/j.jbo.2012.02.001_bib6","first-page":"16","article-title":"Clinical trials in metastatic breast cancer to bone: past\u2013present\u2014future","volume":"5","author":"Body","year":"1995","journal-title":"Canadian Journal of Oncology"},{"issue":"24","key":"10.1016\/j.jbo.2012.02.001_bib7","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.jbo.2012.02.001_bib8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jbo.2012.02.001_bib9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/bjc.1994.344","article-title":"High-dose intravenous pamidronate for metastatic bone pain","volume":"70","author":"Purohit","year":"1994","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2012.02.001_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"8827","key":"10.1016\/j.jbo.2012.02.001_bib11","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jbo.2012.02.001_bib12","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1464-410X.2005.05740.x","article-title":"ZA is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers","volume":"96","author":"Saad","year":"2005","journal-title":"BJU International"},{"issue":"1","key":"10.1016\/j.jbo.2012.02.001_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"Journal of the National Cancer Institute"},{"issue":"5","key":"10.1016\/j.jbo.2012.02.001_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/RHU.0b013e318188b1f3","article-title":"Paget disease of bone: therapeutic options","volume":"14","author":"Silverman","year":"2008","journal-title":"Journal of Clinical Rheumatology"},{"issue":"1","key":"10.1016\/j.jbo.2012.02.001_bib15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/jjco\/hyi005","article-title":"A multicenter and open label clinical trial of ZA 4mg in patients with hypercalcemia of malignancy","volume":"35","author":"Kawada","year":"2005","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.jbo.2012.02.001_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.coc.0000138966.66780.3e","article-title":"Economic evaluation of ZA versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma","volume":"28","author":"Reed","year":"2005","journal-title":"American Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.jbo.2012.02.001_bib17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1464-410X.2008.08034.x","article-title":"Systemic therapy for advancing or metastatic prostate cancer [STAMPEDE]: a multi-arm, multistage randomized controlled trial","volume":"103","author":"James","year":"2009","journal-title":"BJU International"},{"issue":"5","key":"10.1016\/j.jbo.2012.02.001_bib18","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1525-7304(11)70071-7","article-title":"Selected clinical trials in advanced non-small-cell lung cancer","volume":"11","author":"Langer","year":"2010","journal-title":"Clinical Lung Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2012.02.001_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"ZA is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.jbo.2012.02.001_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0960-9776(03)80162-5","article-title":"Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions","volume":"12","author":"Body","year":"2003","journal-title":"Breast"},{"issue":"11","key":"10.1016\/j.jbo.2012.02.001_bib21","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/j.1464-410X.2009.08952.x","article-title":"Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates","volume":"104","author":"Saad","year":"2009","journal-title":"BJU International"},{"issue":"18","key":"10.1016\/j.jbo.2012.02.001_bib22","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly ZA for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1016\/j.jbo.2012.02.001_bib23","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"ZA and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.jbo.2012.02.001_bib24","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s11547-007-0205-x","article-title":"Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions","volume":"112","author":"Quattrocchi","year":"2007","journal-title":"Radiologia Medica"},{"issue":"12","key":"10.1016\/j.jbo.2012.02.001_bib25","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00256-007-0388-1","article-title":"A prospective analysis of CT density measurements of bone metastases after treatment with ZA","volume":"36","author":"Quattrocchi","year":"2007","journal-title":"Skeletal Radiology"},{"issue":"5","key":"10.1016\/j.jbo.2012.02.001_bib26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10585-009-9247-x","article-title":"Radiological changes following second-line ZA treatment in breast cancer patients with bone metastases","volume":"26","author":"Amir","year":"2009","journal-title":"Clinical & Experimental Metastasis"},{"issue":"Suppl. 12","key":"10.1016\/j.jbo.2012.02.001_bib27","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1002\/1097-0142(20000615)88:12+<3033::AID-CNCR20>3.0.CO;2-C","article-title":"Bisphosphonates and breast carcinoma: present and future","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2012.02.001_bib28","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"ZA significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.jbo.2012.02.001_bib29","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00198-009-1077-9","article-title":"HORIZON Pivotal Fracture Trial. Effect of once-yearly ZA on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial","volume":"21","author":"Eastell","year":"2010","journal-title":"Osteoporos International"},{"issue":"7","key":"10.1016\/j.jbo.2012.02.001_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/jso.21145","article-title":"Clinical and radiologic response in patients with bone metastases managed with combined radiotherapy and bisphosphonates","volume":"98","author":"Vassiliou","year":"2008","journal-title":"Journal of Surgical Oncology"},{"issue":"7","key":"10.1016\/j.jbo.2012.02.001_bib31","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/BF00351751","article-title":"Osteodensitometry of vertebral metastases after radiotherapy using quantitative computed tomography","volume":"18","author":"Reinbold","year":"1989","journal-title":"Skeletal Radiology"},{"issue":"3","key":"10.1016\/j.jbo.2012.02.001_bib32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.radonc.2004.01.009","article-title":"CT evaluation of breast cancer patients with osteolytic bone metastases undergoing palliative radiotherapy: a feasibility study","volume":"70","author":"Chow","year":"2004","journal-title":"Radiotherapy and Oncology"},{"issue":"8","key":"10.1016\/j.jbo.2012.02.001_bib33","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3109\/07357909909032841","article-title":"Osteodensitometry of vertebral metastases after radiotherapy using quantitative computed tomography. therapeutic response in skeletal metastases using dual-energy x-ray absorptiometry: a prospective feasibility study in breast cancer patients","volume":"17","author":"Reinbold","year":"1999","journal-title":"Cancer Investigation"},{"issue":"4","key":"10.1016\/j.jbo.2012.02.001_bib34","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/(SICI)1097-0185(199712)249:4<458::AID-AR5>3.0.CO;2-N","article-title":"Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment","volume":"249","author":"Pataki","year":"1997","journal-title":"Anatomical Record"},{"issue":"1","key":"10.1016\/j.jbo.2012.02.001_bib35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1210\/jc.2006-1272","article-title":"Prevention of bone loss in survivors of breast cancer: a randomized, double-blind, placebo-controlled clinical trial","volume":"92","author":"Greenspan","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"30","key":"10.1016\/j.jbo.2012.02.001_bib36","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1200\/JCO.2006.05.9212","article-title":"Phase II trial evaluating the palliative benefit of second-line ZA in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy","volume":"24","author":"Clemons","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.jbo.2012.02.001_bib37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.urology.2007.03.071","article-title":"Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer","volume":"70","author":"Smith","year":"2007","journal-title":"Urology"},{"issue":"22","key":"10.1016\/j.jbo.2012.02.001_bib38","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate ZA","volume":"23","author":"Coleman","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.jbo.2012.02.001_bib39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.trsl.2010.01.002","article-title":"Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate ZA","volume":"155","author":"Mountzios","year":"2010","journal-title":"Translational Research"},{"issue":"6","key":"10.1016\/j.jbo.2012.02.001_bib40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cytogfr.2004.06.004","article-title":"The molecular triad OPG\/RANK\/RANKL: involvement in the orchestration of pathophysiological bone remodeling","volume":"15","author":"Theoleyre","year":"2004","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"5","key":"10.1016\/j.jbo.2012.02.001_bib41","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0002-9440(10)63560-2","article-title":"Receptor activator of nuclear factor kappaB ligand [RANKL]\/osteoprotegerin [OPG] ratio is increased in severe osteolysis","volume":"163","author":"Grimaud","year":"2003","journal-title":"American Journal of Pathology"},{"issue":"1","key":"10.1016\/j.jbo.2012.02.001_bib42","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1464-410X.1991.tb15260.x","article-title":"Morphometric evidence for bone resorption and replacement in prostate cancer","volume":"68","author":"Clarke","year":"1991","journal-title":"British Journal of Urology"},{"issue":"4","key":"10.1016\/j.jbo.2012.02.001_bib43","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1054\/bjoc.1999.1012","article-title":"Markers of bone turnover for the management of patients with bone metastases from prostate cancer","volume":"82","author":"Garnero","year":"2000","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1016\/j.jbo.2012.02.001_bib44","first-page":"917","article-title":"Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer","volume":"62","author":"Yi","year":"2002","journal-title":"Cancer Research"},{"issue":"16","key":"10.1016\/j.jbo.2012.02.001_bib45","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastases","volume":"350","author":"Roodman","year":"2004","journal-title":"New England Journal of Medicine"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137412000024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137412000024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:15:01Z","timestamp":1761941701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137412000024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S2212137412000024"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2012.02.001","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2012.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}